Prosalic0.05%+2%

Prosalic is a topical combination of a potent corticosteroid (betamethasone) and a keratolytic agent (salicylic acid), used for chronic, dry, thickened, and scaly skin disorders that respond to both anti-inflammatory and scale-removing action.

Established/guideline-supported uses

• Chronic plaque psoriasis, including scalp psoriasis, with hyperkeratotic (thickened, scaly) plaques
• Chronic eczema/dermatitis with significant scaling or lichenification
• Lichen planus and other corticosteroid-responsive dermatoses with hyperkeratosis
• Other chronic hyperkeratotic, inflammatory dermatoses where scale removal is needed to allow the steroid to penetrate effectively

The salicylic acid component softens and removes thickened, scaly skin (keratolysis), which also enhances penetration of betamethasone into the affected skin. Prosalic is intended for short-term, corticosteroid-responsive conditions and is not indicated for routine long-term or maintenance therapy.

Each unit of Betamethasone + Salicylic Acid topical preparation (ointment/lotion/cream) typically contains:

• Betamethasone (as betamethasone dipropionate or valerate) — commonly 0.05% w/w
• Salicylic acid — commonly 2–3% w/w (formulation-dependent, e.g., scalp lotion vs. ointment)

Exact strengths vary by brand and dosage form; check the product label/pack insert for the specific concentrations of the marketed brand.

Prosalic combines two complementary topical agents in a single formulation:

• Betamethasone is a synthetic, potent corticosteroid that reduces inflammation, redness, itching, and immune-mediated skin reactions.
• Salicylic acid is a keratolytic agent that loosens and removes excess scale from thickened skin, and also improves penetration of the corticosteroid into the skin.

Together they are formulated as an ointment or lotion for external use on chronic, scaly, inflamed skin lesions such as psoriasis and eczema, most often on the scalp or thickened plaques elsewhere on the body.

Prosalic belongs to the class of topical corticosteroid + keratolytic combinations, used in dermatology for hyperkeratotic, inflammatory skin conditions.

Betamethasone + Salicylic Acid works through two complementary mechanisms:

• Betamethasone is a potent synthetic glucocorticoid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory proteins (e.g., lipocortins) that inhibit phospholipase A2, reducing synthesis of inflammatory mediators (prostaglandins, leukotrienes). This produces anti-inflammatory, antipruritic, and vasoconstrictive effects in the skin.
• Salicylic acid acts as a keratolytic by dissolving the intercellular cement substance that holds together keratinized cells of the stratum corneum, causing desquamation of thickened, scaly skin. This scale removal also increases the surface area and penetration available for betamethasone absorption, enhancing its local efficacy.

The combination in Betamethasone + Salicylic Acid is therefore synergistic: salicylic acid improves steroid delivery while directly reducing scaling, and betamethasone controls the underlying inflammation.

Prosalic is for external (topical) use only. Apply a thin layer/few drops directly to the affected skin or scalp area and gently massage or rub in until absorbed. Do not swallow. Avoid application on broken skin, open wounds, or near the eyes. Wash hands thoroughly after use unless treating the hands.

Clinically significant interactions with Prosalic are uncommon because systemic absorption from topical use is normally low, but the following are recognized concerns:

• Other topical corticosteroids or keratolytic/irritant products (e.g., other salicylic acid products, retinoids, benzoyl peroxide) applied to the same area may increase skin irritation, atrophy, or systemic absorption — avoid concurrent use without medical guidance.
• Other salicylate-containing products (oral aspirin, other topical salicylates) may increase the risk of cumulative salicylate toxicity if used over large areas, especially in children.
• Occlusive dressings or use over large body surface areas substantially increase systemic absorption of both betamethasone and salicylic acid, raising the risk of systemic corticosteroid and salicylate effects.

Most side effects of Prosalic are local and related to the application site:

• Burning, stinging, itching, or irritation at the application site
• Dryness or peeling of the skin
• Skin atrophy (thinning), striae (stretch marks), and telangiectasia with prolonged use
• Hypopigmentation of the treated skin
• Folliculitis, acneiform eruptions, hypertrichosis, or perioral dermatitis
• Allergic contact dermatitis

With prolonged use, use over large areas, or use under occlusion, systemic effects can occur (see Precautions and Warnings), including HPA-axis suppression and salicylate toxicity.

Pregnancy: There are no adequate, well-controlled studies of Prosalic in pregnant women. Topical corticosteroids can be absorbed systemically and may carry a risk to the fetus with extensive or prolonged use; salicylic acid absorbed systemically has also been associated with fetal risk in high doses. Prosalic should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus — consult a physician before use.

Lactation: It is not known whether topical betamethasone or salicylic acid are excreted in human breast milk in clinically significant amounts. Caution is advised; avoid applying Prosalic directly to the breast/nipple area before breastfeeding, and use the lowest effective amount for the shortest duration. Consult a physician before use while breastfeeding.

Use Prosalic with caution and under medical supervision, particularly regarding the following:

• HPA-axis suppression: Prolonged use, use over large body surface areas, or use under occlusive dressings can lead to systemic absorption sufficient to cause hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
• Salicylate toxicity: Extensive application, especially over large areas or under occlusion, can result in systemic salicylate absorption and toxicity (tinnitus, hyperventilation, confusion), particularly in children and patients with renal or hepatic impairment.
• Skin atrophy: Long-term continuous use can cause thinning, striae, and fragility of the skin, particularly on the face and intertriginous areas.
• Avoid on sensitive areas: Do not use on the face, groin, or axillae for prolonged periods, and avoid contact with eyes and mucous membranes.
• Avoid concurrent irritants: Do not use other keratolytic, exfoliating, or irritant topical products on the same area without medical guidance.
• Infection risk: If signs of skin infection develop during treatment, discontinue Prosalic and seek medical advice, as corticosteroids can mask or worsen underlying infections.
• Duration: Long-term continuous therapy should be avoided in all patients; treatment should be limited to the shortest period that controls the condition, with periodic reassessment.

Topical overdose or excessive/prolonged application of Prosalic over large areas can lead to systemic absorption of both components, causing corticosteroid effects (HPA-axis suppression, Cushingoid features, hyperglycemia) and/or salicylate toxicity (ringing in the ears, rapid breathing, nausea, confusion, or in severe cases metabolic disturbance). If accidental ingestion occurs, or if signs of systemic toxicity develop, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to manage significant overdose or ingestion at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Keep the container tightly closed.

Pediatric use

Children are more susceptible than adults to both corticosteroid-induced HPA-axis suppression and salicylate systemic toxicity because of their larger skin-surface-area-to-body-weight ratio. Prosalic should be used in children only under medical supervision, on the smallest affected area, for the shortest effective duration (commonly no more than about 5 days), and occlusive dressings should not be used. Safety and efficacy in young children and infants have not been well established, and use in this group should be avoided unless specifically directed by a physician.

Elderly

Elderly patients may have thinner skin and increased susceptibility to skin atrophy and bruising; use the lowest effective dose and monitor the skin regularly.

Renal/hepatic impairment

Patients with renal or hepatic impairment are at greater risk of systemic salicylate accumulation and toxicity if Prosalic is applied over large areas; use cautiously and avoid extensive application in these patients.

Treatment with Prosalic should be limited to the shortest duration needed to control the condition — typically up to about 2 weeks for scalp/body application in adults, and no more than about 5 days in children — followed by reassessment by a physician. Long-term continuous use should be avoided in all patients due to the risk of skin atrophy, HPA-axis suppression, and salicylate toxicity.

Topical corticosteroid (betamethasone) combined with a keratolytic agent (salicylic acid); dermatological combination product.

Betamethasone + Salicylic Acid acts through the combined effect of a corticosteroid and a keratolytic agent: betamethasone suppresses local inflammatory and immune responses in the skin by inhibiting phospholipase A2 and downstream inflammatory mediator synthesis, while salicylic acid dissolves the intercellular cement of the stratum corneum to shed thickened, scaly skin and enhance corticosteroid penetration. The result is faster resolution of both the scaling and the underlying inflammation compared with either agent alone.

C

Prosalic may be used in children for corticosteroid-responsive, hyperkeratotic skin conditions, but only under close medical supervision because children are more prone to both corticosteroid-related HPA-axis suppression and salicylate systemic toxicity. Use should be limited to the smallest affected area and the shortest effective duration (generally not more than about 5 days), avoiding occlusive dressings and use on the face, groin, or axillae. Safety and efficacy in infants and very young children have not been well established, and use in this age group should be avoided unless specifically directed by a pediatrician.